Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/222233
Title: | Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study |
Author: | Westin, Jason R. Phillips, Tycel Mehta, Amitkumar Hoffmann, Marc S. González Barca, Eva Thieblemont, Catherine Bastos Oreiro, Mariana Greil, Richard Giebel, Sebastian Wei, Michael C. Wang, Jue Bucher, Reinhard Sit, Jason Penuel, Elicia Purev, Enkhtsetseg Yee, Donald L. Bergua Burgues, Juan Miguel |
Keywords: | Medicaments antineoplàstics Limfomes Antineoplastic agents Lymphomas |
Issue Date: | 5-Feb-2025 |
Publisher: | American Society of Hematology |
Abstract: | This phase 2 study evaluated mosunetuzumab plus cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin (Pola-M-CHP) vs Pola-rituximab (R)-CHP for first-line treatment of diffuse large B-cell lymphoma. Patients were randomized 2:1 to receive 6 cycles of Pola-M-CHP or Pola-R-CHP on day 1 of each 21-day cycle. Mosunetuzumab was administered intravenously via step-up dosing during cycle 1 and at 30 mg on day 1 of subsequent cycles. The primary end point was independent review committee-assessed complete response (CR) rate by positron emission tomography-computed tomography. Overall, 62 patients were enrolled and received Pola-M-CHP (n = 40) or Pola-R-CHP (n = 22). CR rates were similar in both arms (72.5% with Pola-M-CHP vs 77.3% with Pola-R-CHP); the 24-month investigator-assessed progression-free survival rate was 70.8% (95% confidence interval [CI], 55.6-86.1) with Pola-M-CHP vs 81.8% (95% CI, 65.7-97.9) with Pola-R-CHP. The most common adverse event (AE) was cytokine release syndrome (68.4%; mostly grade 1 [52.6%], and primarily confined to cycle 1) with Pola-M-CHP and neutropenia/neutrophil count decreased (54.5%) with Pola-R-CHP. Neutropenia/neutrophil count decreased was the most frequently observed grade >= 3 AE in both arms (Pola-M-CHP, 36.8%; Pola-R-CHP, 22.7%). Rates of grade >= 3 AEs (86.8% vs 59.1%), serious AEs (63.2% vs 13.6%), and AEs leading to treatment discontinuation (13.2% vs 0%) were higher with Pola-M-CHP than Pola-R-CHP, respectively. Pharmacodynamic changes were supportive of mosunetuzumab's mechanism of action and its addition to the Pola-CHP combination. Pola-M-CHP, although an active combination, did not demonstrate a clinical benefit over Pola-R-CHP in this small study. This trial was registered at www.clinicaltrials.gov as #NCT03677141. |
Note: | Reproducció del document publicat a: https://doi.org/10.1182/bloodadvances.2024014907 |
It is part of: | Blood Advances, 2025, vol. 9, num. 10, p. 2461-2472 |
URI: | https://hdl.handle.net/2445/222233 |
Related resource: | https://doi.org/10.1182/bloodadvances.2024014907 |
ISSN: | 2473-9537 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
blooda_adv-2024-014907-main.pdf | 1.89 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License